Finoriq research workspace
Boundless Bio, Inc. (BOLD) Historical Metrics
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA. Review BOLD fundamentals, ratios, and historical filing metrics on Finoriq.
Company Snapshot
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
- Company
- Boundless Bio, Inc. (BOLD)
- Ticker
- BOLD
- Market Cap
- $55.5M
- Latest Price
- $2.47
- Industry
- Biotech & Pharma
Boundless Bio, Inc. (BOLD) Current Valuation Metrics
Static valuation preview for Boundless Bio, Inc. (BOLD). Market data retrieved 2026-07-09. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| Earnings YieldLatest TTM net income divided by market cap. | -99.7% | Net Income | TTM Q1 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -83.9% | Operating Cash Flow | TTM Q1 2026 |
| Price / BookMarket cap divided by stockholders' equity. | 0.65x | Stockholders' Equity | Q1 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.